Roche Won’t Match NICE's Excessive Discount Expectations For Kadcyla
This article was originally published in The Pink Sheet Daily
Executive Summary
A discount and even the fulfilment of end-of-life criteria have failed to save Kadcyla at NICE, putting the struggle between health systems’ sustainability and the need for R&D plus innovation in the spotlight.
You may also be interested in...
Patient Engagement Helped Roche’s Kadcyla Get Reimbursement In Scotland
Roche has finally gained a positive recommendation from a health technology assessment body in the UK for its advanced breast cancer therapy, Kadcyla. The Scottish Medicines Consortium gave the product the all-clear after the quality-of-life benefits were highlighted by patients and doctors. It’s future in England is still unclear.
NICE Sends Out Cost Warning By Flatly Rejecting Kadcyla On Price
Not inspired by its clinical effectiveness, NICE has said it will not recommend Roche's “over-priced” Kadcyla for breast cancer.
End-Of-Life-Considerations Fail To Save Lilly’s Alimta For NSCLC At NICE
Britain’s NICE has rejected Eli Lilly’s Alimta for non-small-cell lung cancer, citing cost-effectiveness issues. But the US drug maker still has options to get the drug approved by the pricing watchdog.